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Recent studies suggest that mild hypoxia-induced neonatal seizures can trigger an acute
neuroinflammatory response leading to long-lasting changes in brain excitability along
with associated cognitive and behavioral deficits. The cellular elements and signaling
pathways underlying neuroinflammation in this setting remain incompletely understood
but could yield novel therapeutic targets. Here we show that brief global hypoxia-induced
neonatal seizures in mice result in transient cytokine production, a selective expansion
of microglia and long-lasting changes to the neuronal structure of pyramidal neurons
in the hippocampus. Treatment of neonatal mice after hypoxia-seizures with the novel
anti-inflammatory compound candesartan cilexetil suppressed acute seizure-damage
and mitigated later-life aggravated seizure responses and hippocampus-dependent
learning deficits. Together, these findings improve our understanding of the effects
of neonatal seizures and identify potentially novel treatments to protect against short
and long-lasting harmful effects.
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INTRODUCTION
Hypoxic-ischemic encephalopathy (HIE) is the lead precipitator of neonatal seizures and a leading
cause of long-term disabilities in infants (1). Survivors are at an increased risk of autism, epilepsy,
cognitive and learning difficulties and psychiatric conditions (1, 2). Common clinical practice
is to suppress neonatal seizures by using pharmacotherapies that boost inhibitory drive; such
as phenobarbital. Response rates to phenobarbital are poor however, and treatment does not
attenuate long-term neurological comorbidities (1–3). There are also concerns that phenobarbital
and other anti-seizure medications may be neurotoxic at this age (4). The long-term benefits of
non-pharmacological treatment such as therapeutic hypothermia are not yet established (1, 5).
Therefore, there is an urgent need to identify novel mechanisms and treatments for neonatal brain
damage, seizures and its long-term neurological outcomes.
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Inflammation is increasingly implicated as a pathomechanism
underlying neonatal brain damage following HIE (6–8). Early
inflammation in the developing brain has been implicated in
neurological disorders, including schizophrenia-like behavior
and memory and attention disorders in experimental models
(9–14). A hallmark of neuroinflammation is the induction and
activation of glial cells; microglia and astrocytes, which produce
soluble inflammatory cytokines such as interleukin 1β (IL1β) and
tumor necrosis factor alpha (TNFα) (8). The hippocampus, key
structure in memory and cognition brain function, is particularly
enriched in cytokine receptors and primed to respond to
inflammatory signaling (15, 16). Pre-clinical animal models of
neonatal seizures have recently extended these insights, showing
pharmacologic inhibition of IL1β production reduces neonatal
seizures (17). Exposure of the neonatal brain to infection is also
associated with lasting changes to the morphology of neurons
within vulnerable brain structures (18), such as the hippocampus.
Together, these findings suggest that early-life insults promote
neuroinflammation that contributes to detrimental short- and
long-term neurologic outcomes.
Microglia, which make up 6% of cells in the human brain
(8) are dynamic cells that are critical for initiating and resolving
inflammation in the brain (19–22). Along with their functions as
an immune cells in the brain, microglia also perform neuronal
pruning during a critical stage of brain development (8, 23–27).
Accordingly, disruption of the CR3/C3 (complement receptor
3/complement derived activation fragment 3 pathway) specific
microglia activation pathway during the postnatal period results
in long-term deficits in synaptic connectivity (28).
Sartans are a family of small molecules that have recently
emerged as novel anti-inflammatory drugs; this includes
Candesartan cilexetil (CND). Anti-inflammatory effects of CND
were originally attributed to blockade of the Angiotensin II
receptor type 1 (AT1 receptor), but CND has also been shown
to activate the anti-inflammatory nuclear receptor Peroxisome
proliferator-activated receptor gamma (PPARγ) and, more
recently, inhibit the microglia receptor Toll-like receptor 2
(TLR2) (29). CND recently entered clinical trials for the
treatment of Parkinson’s disease indicating potential use as a
treatment for neuroinflammatory conditions (30–32).
Here, we hypothesize that hypoxic-seizures in the neonatal
period activate inflammation and microglia, leading to
pathological structural changes in the brain. Consequently,
targeting inflammation may improve long term neurological
outcomes after hypoxia-seizures. Here we extended previous
insights into the pathophysiologic consequences of hypoxia-
induced seizures inmice by assessing populations of glia, the time
course of the inflammatory response and attendant structural
changes of neuronal architecture in hippocampal neurons. We
then show CND reduces seizure burden in a model of hypoxia-
seizures when given as a pre-treatment, while post-treatment
with CND reduces neuronal damage, normalized anxiety-like
behavior and susceptibility to a second pro-convulsive agent in
later life. Together, these results extend evidence that neonatal
seizures cause lasting structural changes to the developing
brain and support anti-inflammatory drugs as novel therapeutic
strategies to attenuate the consequences of neonatal brain injury.
MATERIALS AND METHODS
Mouse Model of Neonatal
Hypoxia-Induced Seizures
All animal procedures were performed in accordance with
the principles of European Communities Council Directive
(86/609/EEC, 2010/63/EU), under license (REC#1203b) from the
Department of Health andHealth Products Regulatory Authority
(Ireland) and procedures were approved by the Research Ethics
Committee of the Royal College of Surgeons in Ireland. Neonatal
litters of C57BL/6J mice [weight, 4–6 g; age, postnatal day 6.5–
7.5 (P7)], were obtained from the Biomedical Research Facility,
RCSI. Pups were kept with their dams in a barrier-controlled
facility on a 12 h light–dark (7 a.m.−7 p.m.) standard cycle
with access to food and water ad libitum. All experiments were
performed during the light cycle.
Hypoxia in mouse pups was carried out as previously
described (33). Male and female pups from the same litter were
randomly placed in a clear hypoxic chamber and exposed to a
premixed gas containing 5% O2/95% N2 for 15min at 34
◦C and
80% humidity. Under these conditions, 97% of the pups develop
seizures during and after hypoxia. Normoxic control pups were
placed in the chamber at 21% oxygen (room-air) for the same
period of time. All animals were observed during the 15min
of hypoxia.
For electrographic recording, mice were placed in a stereotaxic
frame and anesthetized with isofurane/oxygen (5% for induction,
2–3% maintenance). Temperature was maintained with a
heat-pad (Harvard Apparatus Ltd., U.K.). Isofurane exposure
was limited to 8–10min (2min induction and maximum of
8min during surgery), where three partial craniectomies were
performed and tethered electrodes (stainless steel screws soldered
to a Teflon-insulated stainless steel wire; E/363/20, Bilaney Ltd.,
U.K. Diameter: 0.56mm) were fixed to approximately 1mm
depth while carefully avoiding the underlying brain surface and
secured into the skull with dental cement. One electrode was
placed in each temporal cortex (−5mm AP and ± 2.5mm ML
from Bregma) and one reference in the cerebellum.
For analysis of EEG data, EEG was recorded using a
Xltek digital EEG-amplifier and digitalized with Twin software
using Notch filter (1Hz high-pass and 60Hz low-pass) (Grass
Technologies Ltd., Warwick, RI). Then, filtered files were
uploaded to LabChart Pro (V7, ADInstruments Ltd.). Seizures
were defined as electrographic polyspike discharges ≥5Hz, ≥
2x baseline EEG amplitude and lasting ≥3 s. EEG total power
[(µV2) is a function of EEG amplitude over time] was analyzed
by integrating frequency bands from 0 to 60Hz. For these
analyses, hypoxia ictal and inter-ictal traces were selected and
the values were normalized to the baseline of each animal (pre-
hypoxia). The number and duration of seizures (measured as
the time from first spike to last spike) were calculated per
hypoxic episode of EEG recording. Total seizure burden was
calculated as the accumulative time that pups ormice were having
electrographic polyspikes discharges. Power spectral density heat
maps were generated within LabChart (spectral view), with the
frequency domain filtered from 0 to 80Hz and the amplitude
domain filtered from 0 to 40mV.
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Behavioral/clinical seizures were scored using a modified
5 points Morrison’s scale for scoring hypoxia/ischemia-
induced seizures in neonatal mice: 0: Normal behavior; 1a:
Immobility/motionless; 1b: Immobility and myoclonic jerks
(spasms/shiver); 2: Rigid/ loss of posture; 3: Circling, swimming,
peddling, tail extension; 4: Spasms, forelimb tonic-clonic;
5: Score 4 repeatedly.
In vivo Administration of Pro- and
Anti-inflammatory Drugs
To assess modulation of inflammation, P7 pups received an
injection of vehicle or drug intraperitoneal [i.p., Candesartan
Cilexetil (CND, Sigma): 1mg.kg−1, vehicle: 1% DMSO in PBS
(29, 34); Pam3CSK4 (Invivogen): 80 µg.kg−1, vehicle: PBS
(35, 36)]. For the measurement of EEG and inflammatory
markers experiments (Figures 1A), drugs were injected 15min
pre-hypoxia. For silver-staining and long-term studies, CND or
vehicle was injected upon hypoxia cessation (Figures 1B). Pups
prepared for EEG recordings were sacrificed immediately upon
cessation of EEG. For long-term studies, pups were subjected to
hypoxia without EEG electrodes and returned to the home cage.
Cytokine Detection by Enzyme Linked
Immunosorbant Assay (ELISA)
Hippocampi were extracted on ice and homogenized in lysis
buffer (20mM Tris HCl (pH: 7.2), 150mM NaCl and 1% Triton
and protease and phosphatase inhibitors [10µg/ml Aprotinin
(Sigma), 10µg/ml Leupeptin (Sigma), 1mM Vanadate (Sigma)
and 1mM PMSF (Sigma)], by dounce homogenizers. Cells debris
and membranes were discarded by centrifugation at 10,000 rpm
for 10min and protein levels were quantified using Pierce BCA
assay kit following manufacturer’s instructions (ThermoFisher).
ELISA was performed as per manufacturer’s instructions
(RND Systems). Briefly, capture antibody was incubated at room
FIGURE 1 | Experimental paradigm of drug administration. (A) Experimental
paradigm for injection of CND or Pam3CSK4 pre-hypoxia induced seizures.
Pups received a single dose of CND and Pam3CSK4 15min before hypoxia.
Electroencephalogram (EEG) was recorded during the 15min of hypoxia. (B)
Experimental paradigm for injection of CND post-hypoxia induced seizures.
Pups were placed on the hypoxia chamber, and received a single dose of CND
after hypoxia. Pups returned to the damn and analyzed for neuronal damage
(72 h post-hypoxia), behavioral tasks (4 weeks post hypoxia) or KA
susceptibility (5 weeks post-hypoxia).
temperature overnight, protein standard curve and 30–50 µg of
protein samples were added in triplicate and incubated for 3 h
at room temperature. Next, the detection antibody was added
to each well and incubated at room temperature for 2 h. For
visualization of the signal, a solution of streptavidin-HRP was
added at a 1:40 dilution per well and a mix containing equal
volumes of Color Reagents A and B. Finally, the enzymatic
reaction was stopped and the plate was read immediately at 570
and 450 nm.
The cytokine concentration was calculated following
manufacturer recommendation. Briefly, the 570 nm values were
subtracted from the 450 nm values, standard curve values were
plotted in GraphPad (Prism v7) and a line of best fit (second
order polynomial) was generated. The amount of protein was
extrapolated and the average of the triplicate was taken. The
concentration was then normalized per mg of total protein in
the tissue.
Quantitative Real Time PCR
Hippocampi were isolated and total RNA was extracted
using Trizol method as described previously (37). RNA
concentration was determined using NanoDrop 2000, and RNA
purity was measured by establishing the ratio of absorbance
between 260 and 280 nm (260/280 ratio). One microgram
of total RNA was retro-transcribed using SuperScript III
Reverse Transcriptase.
Quantitative real-time PCR was performed using a
LightCycler 1.5 (Roche Diagnostics) in combination with
QuantiTect SYBR Green PCR kit (Qiagen) as per manufacturer’s
protocol. Specific primers were purchased from Sigma: IL1β (F:
5′ tgaagttgacggaccccaaa 3′, R: 5′ agcttctccacagccacaat 3′); Tnfα
(F: 5′ ctcttcaagggacaaggctg 3′, R: 5′ cggactccgcaaagtctaag 3′); Iba1
(F: 5′ tggaggggatcaacaagcaa 3′, R: 5′ accccaagtttctccagcat 3
′
);Gfap
(F: 5′ agaaaaccgcatcaccattc 3′, R: 5′ tcacatcaccacgtccttgt 3′)
and β-Actin (F 5′-ggttggccttagggttcagg-3′, R 5′-gggtgtgatggtgg
gaatgg-3′).
Flow Cytometry-FACS
Prefrontal and temporal cortex and whole hippocampi were
dissected from mice and processed for flow cytometry. Upon
being removed from the skull the brain was stored in
MACS tissue solution (Miltyeni). Tissue was dissociated using
MACS Miltyeni Neural Dissociation kit (Papain) as per the
manufacturer’s instructions. Tissue was dissociated and filtered
through 70µm mesh filters (MACS). This cell mixture was
then centrifuged at 1,200 rpm for 5min and the cell pellet
was suspended with FACS buffer (0.5M EDTA, 1% FBS in
PBS). 2.5 × 105 cells were blocked with FcR Block solution
(1 µL every 106 cells) for 15min on ice and then stained
with anti-CD45-PE (1:100. eBiosciences. Thermo Fisher) and
anti-CD11b-FITC (1:100. BioLegend) or appropriate control-
IgG antibodies for 30min on ice. Cells were then washed in
FACS buffer and analyzed on FACS (BD FACSCANTO
TM
II).
The data were analyzed with BD FACSDIVA
TM
software. The
microglia subpopulation was defined as percentage of cells in the
CD11b+/CD45low gate (Supplementary Figure 1).
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Histopathology and Immunofluorescence
Bromo-Deoxy-Uridine (BrdU) Detection
BrdU was used to label dividing cells in the brain. Pups received a
single injection of 50mg.kg−1 of BrdU intraperitoneal 6 h pre-
hypoxia. Seventy-two hours post hypoxic-seizures pups were
perfused with cold PBS followed by 4% PFA. Brains were then
embedded in agarose and cut at 50µm using a Vibratome
(VT1000). First, slices were incubated in 2N hydrochloric acid
(HCl) at 37◦C for 30min, then, sections were incubated in borate
buffer for 15min to neutralize any residual acid and prevent
any further permeabilization. Sections were then washed in TBS
for 5min and rinsed in blocking solution (3% horse serum in
0.1% Triton X100-TBS). All sections were incubated with mouse
anti-BrdU (1:400, Roche).
Slices were washed in TBS and incubated with rabbit anti-
NeuN (1:500, Merck Millipore), rabbit anti-GFAP (1:500, Roche)
or goat anti-Iba1 (1:500, Wako). Then, slices were washed,
and incubated in secondary fluorescent antibodies, anti-mouse
Alexa-488, anti-rabbit Alexa-568 anti-goat Alexa-568 (1:500,
Invitrogen) in dark. Remaining antibody was washed with TBS
and finally sections were incubated in Hoechst nuclear stain
for 10min. Sections were mounted onto slides and covered
with FluorSave (Sigma). Brain slices (medial hippocampus) were
visualized under the fluorescence microscope (Leica, DM4000B).
Silver Staining
For histological analyses 72 h post hypoxia, pups were
transcardially perfused with cold PBS followed by cold 4%
PFA/2.5% glutaraldehyde in 0.1M phosphate buffer, and
post-fixed in the same solution. Brains were then fixed in
4% agarose and sectioned using a Vibratome at 50µm (Leica
VT1000). Then, sections were mounted onto superfrost slides
(ThermoScientific) and dried overnight at 37◦C and processed
using a method developed by Gallyas et al. (38), with minor
modifications (33). Briefly, after fixation slices were rinsed in 1%
acetic acid, then sections were dehydrated with 1-isopropanol
at increasing concentrations (50, 75, 97%). Finally, sections
were esterified with 100% 1-propanol containing 0.8% sulfuric
acid (Sigma) and incubated at 56◦C for 18 h. Upon rehydration
with decreasing concentration of 1-isopropanol and 1% acetic
acid treatment, sections were developed in a mix of equal
volumes of 10% Na2CO3 and 0.2% AgNO3, 0.25% NH4NO3,
2% tungstosilicic acid (Sigma) and 0.4% formaldehyde (Sigma).
Sections were dehydrated, cleared with three rounds of histoclear
and covered with DPX (Sigma-Aldrich). Semi-quantitative
analysis of silver staining (medial hippocampus) was performed,
by an experimenter blinded to the condition, under 20X lens
magnification under the microscope (Leica DFC300FX). Two
consecutive slides were counted per condition and the average
number of positive cells from both slides was calculated.
Intracellular Injection and Cell
Reconstruction Analysis
Neuronal labeling technique was carried out as previously
described (39). Mice exposed to normoxia or hypoxia 5 weeks
earlier were used in the analysis. Pyramidal cells from the
CA1 subfield (medial hippocampus) of 150µm vibratome-
prepared sections were individually injected with Lucifer Yellow
by continuous current, filling individual dendrites until the
distal tips of each cell fluoresced brightly, indicating that
the dendrites were completely filled and ensuring that the
fluorescence did not diminish at a distance from the soma.
Sections were immunostained using rabbit polyclonal antibodies
against Lucifer yellow produced at the Cajal Institute, followed
by streptavidin coupled to Alexafluor 488 (1:1,000, Molecular
Probes). From each mouse 3–6 neurons were randomly selected
and the basal tree (stratum oriens) was scanned from the soma
to the tip of the longer dendrite using LSM710 confocal laser
scanning microscope (Carl Zeiss, ZEN 2009) with 20x 0.5NA
(zoom 1.0), objective taking a z-stack with an interval of 1µm
between single images. To analyze the complexity of the dendritic
tree, Z-stacks were combined in Image J and Neuron J plugin
(40, 41) was used to manually draw the dendritic tree using the
maximum intensity projection. All morphological analysis was
performed blindly by the same investigator.
For the overview image (Figure 2A), image was scanned with
multiple fields of view of a 20x 0.8 objective, zoom 0.6, on a LSM
710 confocal microscope with an overlap of 10% of the FOV size
using the multiple time series macro in ZEN 2009. Images were
subsequently stitched using the stitching plugin (http://fly.mpi-
cbg.de/~preibisch/contact.html) running in Image J (version
1.50i, Wayne Rasband, NIH).
Cognitive and Behavioral Testing
Open-Field Test
Cognitive functions and behaviors were assessed in mice 4 weeks
after hypoxia. To assess mobility, mice were studied in the
open field test. The open-field test consists of an open glass
box (30 × 30 × 20 cm) and was carried out prior to the novel
object-location task (see below). Each mouse was placed in the
center of the arena and allowed to explore for 10min. Total
distance traveled, velocity (cm.s−1), freezing episodes, number
of crossings and average time spent in specific central/peripheral
zones of the arena were quantitatively analyzed using video
tracking (Ethovision, Tracksys, Nottingham, U.K.). The central
and peripheral zones were designated post-testing using the
Ethovision software.
Light-Dark Box Test
The test apparatus consisted of an open glass box (30 × 15 ×
20 cm) connected to an acrylic dark box (30 × 15 × 20 cm)
via an entrance. The light area was illuminated from above by
a white lamp bulb (60 W/600 lux). Mice were habituated in the
behavioral recording room 2 h prior to the beginning of testing.
Mice were placed in the center of the light area, facing away from
the entrance of the dark area, and were allowed to explore the
apparatus for 10min. Anxiety-related behavior was quantitatively
assessed in terms of latency to enter the dark area by Ethovision
tracking software.
Novel Object-Location Test
The test was carried out over two consecutive days in 10min
sessions. Day 1 (habituation day), mice were allowed to explore
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FIGURE 2 | Hypoxia-induced seizures induce acute inflammation and
microglia proliferation in a neonatal mouse model. (A,B) IL1β mRNA and
(Continued)
FIGURE 2 | protein levels are increased acutely in hypoxia-exposed pups
compared to control [n = 6 per group. *p < 0.05. A, F: 4.854, t: 3.028 (vs.
control), t: 0.568 (vs. 6 h). B, F: 4.477, t: 2.485)] (C,D) TNFα mRNA and protein
levels are increased acutely in the hippocampus in hypoxia exposed mice
compared to control [n = 6 per group. *p < 0.05. C, F: 6.736, t: 2.975 (vs.
control), t: 2.138 (vs. 6 h). D, F: 1.322, t: 2.260)]. (E,F) Levels of IL1β and TNFα
were normalized at 1 week and 6 weeks after hypoxia (n = 6 per group). (G)
Representative confocal images of double-staining cells with BrdU and NeuN
(neuronal marker, NeuN/BrdU) or GFAP (astrocytic marker, GFAP/BrdU) or Iba1
(microglia marker, Iba1/BrdU) in the hippocampus 72 h post hypoxia. Scale
bar: 10µm. (H–J) Quantification of the percentage of BrdU positive cells are
also positive for NeuN (H), GFAP (I) or Iba 1 (J) (n = 16 per group. **p < 0.01.
J, F: 1.471, t: 3.133). (K) Representative scatter plot shows the distribution of
CD45 and CD11 from control brain. (L) Quantitative analysis of the percentage
of CD11+/CD45low as a representation of the microglia population in control
and hypoxia exposed pups (n = 6 per group. **p < 0.01. F: 2.397, t: 3.831).
the arena without objects (10min) followed by 3 sessions with
two objects (10min each session); on day 2 (test day), mice were
placed in the same arena with one of the objects moved to a novel
position. Object exploration was manually recorded and defined
as the time mice were interacting with the objects with their nose
or paw within 1 cm of the objects (3). To calculate the percentage
of time with the novel-object, the following equation was used:
(A)/(A+B)∗100. A=Time spend with novel object. A+B=Time
spend with both objects.
Seizure Susceptibility Testing at Adulthood
A sub-group of pups subject to manipulations at P7 were
later exposed to chemoconvulsant to assess seizure severity.
For these studies, mice at 6 weeks of age received a single
injection of kainic acid (15mg.kg−1; KA, intraperitoneal). All
mice receiving KA were recorded for both electrographic (EEG)
and behavioral seizures. Electrode implantation, EEG recording
and quantification were performed as previously described
(3, 33). Briefly, mice were injected with KA and monitored
for 60min post-KA. During this time all clinical seizures were
monitored in 5min intervals. Behavioral scores were based on a
6-point Racine-like scale, as described previously (33). Racine’s
behavior scale: 0: normal behavior; 1: Immobility; 2: Freezing/tail
extension; 3: Repetitive movements/ head bobbing; 4: Rearing
and falling; 5: Tonic-clonic; 6: Repeated tonic-clonic. EEG was
quantified as before.
Statistical Analysis
All analyses were carried out by an observer blinds to the
experimental condition. All data are presented as Box and
Whiskers plots to show first and third quartiles, median and
minimum and maximum of all the data. All statistical tests
were carried out in the Graph-Pad Prism software. Two group
experiments were analyzed using Mann Whitney U-test for
nonparametric distributed data. Multi-group comparisons were
made using one-way ANOVA with Bonferroni post-test. P-value
of < 0.05 was considered significant.
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FIGURE 3 | Hypoxia induces seizures at P7 results in neuronal morphology
alterations later in life. (A) Field view of hippocampi showing Lucifer yellow
(Continued)
FIGURE 3 | injected CA1 neurons (green) and nuclei (Red). (B) Higher
magnification CA1 injected neuron from the control (left) and hypoxia (right)
group. (C) Representative images of the basal dendritic tree from the control
and hypoxia group. (D) Number of basal dendrites per soma (F: 3.354, t:
6.854), (E) total dendritic length (F: 2.322, t: 2.435), (F) length of an individual
dendrite (F: 1.588, t: 2.818) and (G) number of branches in control and
hypoxia group (F: 16.90, t: 4.135). Scale bar: (A) 500µm and (B,C) 10µm.
(n = 17–20 neurons per group from 4 mice per condition). (*P < 0.05, **p <
0.01, ***p < 0.001).
RESULTS
Hypoxia-Induced Seizures Produce an
Acute Inflammatory Response
We have previously reported that hypoxia-seizures during the
neonatal period induces neuroinflammatory signaling and long-
lasting impairment of neurological function in mice (3, 33).
Now, we evaluated the levels of pro-inflammatory cytokines post-
hypoxia. Hippocampi from control and hypoxia-exposed pups
were isolated and levels of the pro-inflammatory cytokines, IL1β
and TNFα, were evaluated by qPCR and ELISA (Figures 2A–F).
Interestingly, we observed an increase in both cytokines in the
first 24 h after hypoxia-seizures (Figures 2A–D). This increase
was transient and not observed in samples collected from mice
1 week and 6 weeks after hypoxia (Figures 2E,F). Thus, hypoxia-
seizures induce short-lasting increases in inflammatory cytokines
in this model.
Hypoxia-Seizures Induces a Selective
Increase in the Number of Microglia in the
Neonatal Brain
We evaluated whether the acute increase in pro-inflammatory
cytokines lead to changes to the major resident cell populations
in the immature brain (32). Here, we first evaluated whether
hypoxia-induced seizures result in altered neurogenesis or
gliogenesis in the hippocampus. The cell division marker BrdU
was injected pre-hypoxia and then tissue sections were collected 3
days later and co-labeled for markers of mature neurons (NeuN),
astrocytes (GFAP) or microglia (Iba1).
No differences were observed in the percentage of NeuN+ or
GFAP+ cells co-labeled with BrdU between hypoxia-seizure and
control groups (Figures 2G–I). However, numbers of Iba1-BrdU
double-positive cells were increased in the hypoxia-seizure group
compared to control (Figures 2G,J). Thus, hypoxia-seizures
appears to selectively expand the microglia population in this
model, at this time following seizures.
To support these findings, we used Fluorescence-Activated
cell sorting (FACS) analysis to quantify microglia cells obtained
from brains of mice 72 h after hypoxia-seizures. Control pups had
∼6,500 microglia per 1 × 105 cells, which corresponds closely to
the expected proportion of these cells [∼6.5% of the total number
cells (Figures 2K,L)] and is similar to assessments of neocortical
microglia populations in the developing human brain (42, 43).
Corroborating BrdU results, hypoxia-exposed pups had ∼8,000
microglia per 1 × 105 cells, which corresponded to ∼8% of the
total cell population (Figures 2K,L).
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Together, this data showed that neonatal hypoxia-seizures
cause an increase in the population of microglia in the
developing brain.
Hypoxia Induces Long-Lasting Changes in
Neuronal Morphology in the CA1 Subfield
of the Hippocampus
It has now emerged that a major function of microglia is
early dendritic pruning (25). We hypothesized that the increase
in neuro-inflammation and brain resident microglia would
be associated with long-lasting alteration of the structure of
pyramidal neurons, principle excitatory neurons. To test this
idea, P7 pups were subjected to hypoxia-seizures and then
5 weeks later (at 6 weeks old) brain slices were obtained.
CA1 pyramidal neurons were individually injected with Lucifer
yellow. The complexity of the basal dendritic tree (stratum oriens)
was analyzed by confocal microscopy (Figures 3A–C).
In the control group, 20 neurons (from 4 mice) and
a total of 23,706µm dendritic length were analyzed. On
average, a neuron from the control group showed 3.7 dendrites
(primary branches coming from the soma) (Figure 3D) with
a total dendritic length of 1,185µm (Figure 3E). Analysis of
individual dendrites from the control group showed that a single
dendrite was on average 197.3µm long (Figure 3F) and one
dendrite presented ∼1.1 branches (Figure 3G). In contrast, CA1
pyramidal neurons from mice previously subject to hypoxia-
seizures showed on average 7.9 dendrites (primary branches,
Figure 3D) and a total dendritic length of 1,575µm (Figure 3E).
Our results correspond to an increase of 30% of the basal
dendritic extension in mice previously subject to hypoxia-
seizures compared to the control group. Additionally, individual
dendrites were 150.3µm in length, 25% shorter than a dendrite
from the control group (Figure 3F) and presented 0.4 branches
(Figure 3G). These findings indicated that neonatal hypoxia-
induced seizures induce lasting and substantial morphological
alterations of principal excitatory neurons in the stratum oriens
from mouse hippocampus.
Anti-inflammatory Drug CND Reduces
Seizure Severity Following
Neonatal Hypoxia
Given the inflammatory response induced by neonatal hypoxic-
seizures and evidence that inflammation is a key patho-
mechanism after hypoxia-induced seizures, we hypothesized that
targeting inflammation would reduce seizures in the P7 model.
For this, we selected the anti-inflammatory drug CND. CND was
FIGURE 4 | Targeting inflammation modulates hypoxia-induced seizures in P7 mice (A) Representative EEG traces from mice pre-treated with vehicle or CND and
exposed to hypoxia-induced seizures. (B–D) Quantification of EEG files show that mice treated with CND have a delayed onset to first seizures (B; F: 8.309, t: 3.386),
further, these mice also have significantly reduced in total power (C; F: 5.486, t: 3.361) and seizure burden (D; F: 1.913, t: 3.230) (n = 5–7 per group. *p < 0.05, **p <
0.01). (E) CND-treated pups experienced also significantly shorter seizures (n = 5–7 per group. *p < 0.05. F: 2.466, t: 2.411). Mice exposed to CND have a reduction
in IL1β (F; F: 778.6, t: 2.085), without affecting TNFα (G) (n = 5 per group. *p < 0.05).
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FIGURE 5 | CND protects neonates against the neuronal damage induced by
hypoxia. P7 pups were exposed to normoxia or hypoxia and receive a single
dose of vehicle (veh) or CND just after hypoxia. (A) Graph shows the number
of silver-staining positive cells in the four experimental paradigms. Note: CND
protects against hypoxia induced neuronal damage [n = 6–8, **p < 0.01,
(Continued)
FIGURE 5 | compared to control. F: 11.500, t: 5.141 (vs. control), t: 4.308 (vs.
CND), t: 4.553 (vs. Hyp-CND)] (B) Representative high magnitude (40x) silver
staining images from the hypoxia group. Scale bar: 10µm. (C) Representative
10x silver staining images of the hilus 72 h post-treatment. Scale bar: 50µm.
(D) Representative 20x images of the hilus area of control, CND and/or
hypoxia exposed mice. Scale bar: 20µm.
administrated 15min before hypoxia, and electroencephalogram
(EEG) was recorded and quantified (Figures 1A, 4A). CND
injected mice showed a delay in seizure onset, a reduction in total
power, seizure burden and duration of a single seizure compared
to the vehicle injected pups (Figures 4B–E). As expected, levels of
IL1βmeasured 24 h later were reduced in the CND-injected pups
compared to vehicle injected pups (Figure 4F) and no changes
were observed on TNFα (Figure 4G).
We next hypothesized that enhancing inflammatory responses
should produce the opposite effect in the model. To test
this idea, mice were pre-treated with the pro-inflammatory
and microglia activating drug, Pam3CSK4 (44). As expected,
total power, seizure burden and inflammatory markers were
significantly higher in the PAM-injected mice compared to
vehicle (Supplementary Figure 2), suggesting that modulating
inflammation is sufficient to alter seizure severity in neonates.
CND Reduces the Neuronal Damage
Induced by Hypoxia-Seizures in Mice
Next, we sought to determine if post-treatment with CND, a
more clinically-relevant scenario would alter outcomes. Pups
were subjected to normoxia or hypoxia and immediately after
received a single dose of vehicle or CND. As previously described
(3, 33), sporadic silver (SS) positive cells were observed in
the control group (Figures 5A–D). Pups subject to hypoxia-
seizures had significantly increased SS-positive neurons in the
hippocampus (Figures 5A–D). Treatment of mice with CND
alone or in combination with hypoxia was associated with
only occasional silver positive cells similar to numbers in non-
hypoxic controls (Figures 5A–D). These data suggested that
post-treatment with CND protected against hypoxic-seizure
neuronal damage.
Effects of CND and/or Hypoxia-Induced
Seizures on Locomotor Activity Later
in Life
Previously, we have reported that hypoxia-seizures at P7 induced
anxiety-like behavior, memory impairment and increases seizure
susceptibility later in life (3). Now, we speculated whether post-
treatment with CND may normalize the neurological outcomes
associated with neonatal hypoxia-seizures (3).
Separate groups of mice were injected with CND just after
hypoxia at P7 and returned to the home-cage for 4 weeks and
assessed at 5 weeks of age. First, the four different experimental
groups (Control: Con; CND; Hypoxia: Hyp; Hypoxia-CND:
Hyp-CND) were evaluated in an open arena (open-field task),
and recorded for 10min (Figures 6A–D).
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FIGURE 6 | CND normalizes the anxiety-like behaviors and memory impairment caused by hypoxia-induced seizures. (A–D) Motor and anxiety-related behavior in
mice exposed to hypoxia and/or receiving CND at P7. (A) Representative behavior tracking of controls, CND, hypoxia and hypoxia-CND in the open field test. (B–D)
(Continued)
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FIGURE 6 | Distance move, time spent in periphery and freezing time in the 10min of recording (n = 11–13). (E,F) Representative view above the light-dark box
shows the location of the mouse at the start of the test and the tracks and graph quantifying the latency to the first transition to the dark zone [n = 11–13, *p < 0.05,
**p < 0.01 compared to control, CND and Hyp-CND group. F: 4.036, t: 3.127 (vs. control), t: 1.723 (vs. CND), t: 2.918 (vs. Hyp-CND)]. (G,H) Schematic and
quantification of the novel-object position test [n = 11–13, *p < 0.05, **p < 0.01 compared to control, CND and Hyp-CND group. F: 7.515, t: 3.126 (vs. control), t:
3.392 (vs. CND), t: 4.565 (vs. Hyp-CND)].
Locomotor behaviors were analyzed over the complete 10min
recording. There were no differences in the parameters analyzed
including the distance moved, time spent in the periphery
and freezing time (Figures 6A–D). Thus, CND alone or in
combination with hypoxia did not affect locomotor activity.
CND Improves Anxiety-Like Behavior
Induced by Hypoxia-Induced Seizures
As an assessment of anxiety-like behavior, mice were tested in the
light-dark box task, with latency to enter the dark area used as an
index of anxiety-like behavior (Figures 6E,F) (45). Control mice
explored the light area for approximately 10–30 s before entering
the dark area (Figures 6E,F). Similar behavior was observed
in the normoxic pups that received CND. In contrast, and as
reported previously (3), hypoxia-exposed mice moved directly
into the dark area following release into arena (Figures 6E,F).
However, the pups which received a single dose of CND after
hypoxia at P7 explored the light area for 10–30 s, similar to the
control group (Figures 6E,F).
CND Protects Against Memory Dysfunction
Caused by Hypoxia-Induced Seizures
We also assessedMouse performance in the novel object-location
task, a test of hippocampal function (46, 47) (Figures 6G,H).
First, the total time spent with both objects was assessed. All
experimental groups generally spent equal amounts of time
interacting with both objects (Con: 22.7 ± 3.1 s; CND: 23.8 ±
2.3 s; Hyp: 21.7± 4.4 s and Hyp-CND: 20.2± 2.9 s).
When the percentage of time with the novel object-location
was evaluated, the control group spent ∼60% of the time with
the object at the novel location (Figures 6G,H). As previously
observed (3), the hypoxia-exposed pups spent 42% of the
time interacting with the novel-location object (Figures 6G,H).
However, the pups which received CND alone or after hypoxia
explored the novel location for ∼60% of the time, similar to
the control group. When males and females were compared, no
differences between sex were observed (Supplementary Table 1).
This data showed that CND protected against the impairment of
memory function caused by hypoxia-induced seizures.
CND Reduces the Susceptibility to
KA-Induced Seizures in Mice Exposed to
Hypoxia-Induced Seizures During the
Neonatal Period
There is a long-standing association between early-life neonatal
seizures and later life epilepsy. To test whether CND alters later-
life seizure susceptibility we challenged the four different groups
of mice (Con, CND, Hyp, and Hyp-CND) at 6 weeks of age with
15mg.kg−1 i.p. of the chemoconvulsant KA. EEG and behavior
were video-recorded for 60min after KA injection (Figure 7).
EEG analyses showed that control mice developed
typical epileptiform discharges 20–30min post-KA injection
(Figures 7A–E). In contrast, mice subject to neonatal hypoxia-
seizures displayed a shorter time to seizure onset after KA
challenge compared to the other groups (Figures 7A–E). Pups
that received CND alone or CND after hypoxia developed
similar seizure-like activity to controls after KA injection
(Figures 7A–E). Quantitative analysis of the EEG supported
these findings, when power and seizure burden were evaluated,
we observed similar results. Hypoxia-seizure mice had higher
EEG power and seizure burden after KA compared to controls,
whereas CND and hypoxia-seizure mice given CND had a
similar response to KA as the control group (Figures 7F,G).
Similar results were observed when the duration of an individual
seizure was evaluated with hypoxia-seizure exposed mice
experiencing longer seizures compared to the control and CND
and hypoxia-seizure CND groups (Figure 7H). When males
and females were compared, no differences between sex were
observed (Supplementary Table 2). No differences in clinical
seizure behavior were observed between groups during the
recordings (Figure 6I).
DISCUSSION
In the current work, we present evidence that hypoxia-induced
seizures activate neuro-inflammation and increase microgliosis
in the developing mouse brain. Hypoxia-seizures provoked
upregulation of inflammatory cytokines and aberrant neuronal
morphology in pyramidal neurons from the hippocampus. We
show that a currently FDA-approved drug, the anti-inflammatory
compound CND, not only suppresses acute hypoxia-induced
seizures but also, reduces later-life anxiety-like behavior, seizure
susceptibility in mice and preserves memory function. These
results identify a novel experimental therapy that may attenuate
long-term comorbidities.
Our study provides evidence that hypoxia-induced seizures
increase microgliogenesis and elicit an acute inflammatory
response, typified by an acute increase in IL1β. It has recently
emerged that microglia perform critical functions during
brain development including dendritic pruning (8, 23–26). An
important finding in the present study was that pyramidal
neurons in the CA1 subfield of mice subjected to hypoxia-
induced seizures in the neonatal period developed shorter
dendrites with fewer branches. This would be consistent with
increased neuro-inflammation, and, perhaps due to the increased
number of microglia (48). Notably, perinatal activation of
inflammation by the viral mimetic PolyI:C, in rats reduces
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FIGURE 7 | CND improves the susceptibility to develop seizures later in life after hypoxia-induced seizures in a neonatal mouse model. Five weeks after neonatal
treatment, mice were implanted with electrodes and challenged with systemic KA (15mg.kg−1), EEG and behavior were recorded. (A–D) Representative
(Continued)
Frontiers in Immunology | www.frontiersin.org 11 July 2019 | Volume 10 | Article 1752
Quinlan et al. CND Improves Hypoxia-Seizures in Neonates
FIGURE 7 | spectrograms and corresponding EEG traces from the control (A), CND (B), Hypoxia (C), and hypoxia-CND group (D). (E–H) Quantification of seizure
onset, total power, total seizure burden, and seizure duration during the 60min of recording. (E) Seizure onset was earlier in the hypoxia group compared to the
control, CND and Hyp-CND group (n = 11–13, **p < 0.01 compared to control, CND and Hyp-CND group. F: 11.41, t: 3.896 (vs. control), t: 4.247 (vs. CND), t: 5.387
(vs. Hyp-CND)]. (F) Total power was higher in the hypoxia group compared to the control, CND and Hyp-CND group [n = 11–13, *p < 0.05 compared to control,
CND and Hyp-CND group. F: 10.85, t: 3.183 (vs. control), t: 4.713 (vs. CND), t: 5.051 (vs. Hyp-CND)]. (G) Similar results were found in seizure burden in the hypoxia
group [n = 11–13, ***p < 0.001 compared to control, CND and Hyp-CND group. F: 25.89, t: 6.514 (vs. control), t: 7.038 (vs. CND), t: 7.585 (vs. Hyp-CND)]. (H)
Hypoxia-exposed pups developed on average longer seizures [n = 11–13, ***p < 0.001 compared to control, CND and Hyp-CND group. F: 18.000, t: 4.555 (vs.
control), t: 6.050 (vs. CND), t: 6.381 (vs. Hyp-CND)]. (I) Seizure behavioral score taken every 5min over the 60min period using the modified Racine scale for
mice (n = 11–13).
neuronal complexity in DG neurons in adulthood, and
animals later developed schizophrenia-like behavior (49, 50).
Morphological analysis of hippocampal neurons from patients
with autism and schizophrenia also found shorter dendrites
with reduced dendritic branching in pyramidal neurons (51),
suggesting there is a casual link between neuronal morphology
and behavioral outcomes. Accordingly, we speculate that
independent of the initiating inflammatory response, sterile or
infectious, inflammation caused by hypoxia-seizures leads to
microglial activation and thus aberrant neuronal morphology,
and ultimately enhancing the propensity for neurological
disorders. Indeed, slight changes in the morphology of the
dendritic tree of pyramidal neurons, particularly the dendritic
length, alters the neuronal activity and ultimately cognition (52).
In this study, we have focused on the hippocampus due to
its vulnerability to inflammation. The hippocampus presents
the highest density of cytokines receptors compared to other
areas of the brain, making it especially vulnerable to an
inflammatory response (15, 16). However, we cannot discard
the effects of hypoxia-seizures on other areas of the brain
which may provoke a similar inflammation response along with
morphological changes and ultimately contribute to the same
neurological outcomes.
In the present study we observed that CND, a drug
approved by the FDA and in clinical trials for Parkinson’s
diseases (31, 32), improves acute and long term outcomes
following hypoxia-seizures in mice. Specifically, we observed
that mice pre-treated with CND experience milder seizures
during neonatal hypoxia. This is consistent with previous
studies showing inhibitors of neuroinflammation protect against
neonatal seizures (17). More importantly, post-treatment of
pups subject to hypoxia-seizures reduced neuronal damage
and mice performed better in hippocampal function-dependent
tasks at adulthood. Taken together, these data suggest that
targeting inflammation in the neonatal period may have both
anti-seizure actions as well as protecting against the long-
term consequences of hypoxia-induced seizures. Further studies
would be required to elucidate whether CND elicits direct
anti-seizure effects, or is protecting through a blunting of the
inflammatory response, which has been shown to “prime” the
brain for hyper-excitability (53, 54).
In our current study, we did not observe sex differences
between males and females in the novel object location task
or in the seizure susceptibility test, e.g., seizure onset, total
power, seizure burden. We do acknowledge that the present
model in mice may not capture the full spectrum of sex
differences reported clinically in babies. Sex differences have
been seen in humans in the response to neonatal brain
damage, with boys developing worse outcomes compared to
girls suffering from neonatal brain damage at birth (55, 56).
Nevertheless, it is interesting to consider that similar outcomes
might be produced by different mechanisms of action in
males and females mice. The developing male brain is in a
higher state of excitation and has longer periods of GABA-
directed excitatory responses than females, while, microglia
activation may have a favorable effect on females and not in
males (57).
Neuroinflammatory signaling is an essential component
in responding to injury and studies show that inhibition
can also produce deleterious effects (58). Given this critical
developmental stage in both neuronal maturation and immune
function development, it would be pertinent to suggest that
inhibiting the immune response at this time would also
produce negative long-term outcomes. However, we did not
observe any negative outcomes in those mice treated only
with CND, suggesting that it is relatively safe to give in
the neonatal period. Indeed, there have been several random,
double-blinded control trials on the safety and tolerability
of CND in adults, which have confirmed its neuroprotective
properties and safety profile in Parkinson’s disease (31). There
is certainly a need for a safe and effective therapy for
neonatal seizures. Current treatments are ineffective in about
half of cases and there is concern anti-seizure drugs may
induce negative neurological outcomes (3, 59–61). Notably,
phenobarbital-treated children present with lower IQ ratio
than un-treated children (59, 61). Likewise, a clinical trial of
bumetanide, which may enhance inhibition in the brain, was
halted due to a high occurrence of hearing loss in infants
(1, 62). The efficacy of non-pharmacologic treatments, such as
therapeutic hypothermia, is also uncertain with treated infants
displaying lower IQ scores at follow-up and no improvement in
mortality (1).
A number of questions remain to be answered: 1. Would
we observe a similar response to CND in other models? For
example, a premature model of neonatal encephalopathy or
a model of more severe hypoxia. Since rodent models of
encephalopathy in premature infants also feature inflammation
and activation of microglia we can speculate that CND and anti-
inflammatory drugs may have a similar protective effect (63).
Since hypoxia-induced seizures in our model are insufficient
to cause neuronal death we do not know if CND can protect
against cell loss. This could be tested, for example in models
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with active neuronal death, such as the hypoxia-ischemia
model in rats (64). Nevertheless, CND reduces the neuronal
injury observed by silver staining. 2. It would be important
to compare how CND performs relative to an approved anti-
inflammatory drug. Would we observe similar effect using
common used anti-inflammatory drugs in the clinic? Future
extensive side-by side studies will be necessary to address
this question. Nevertheless, non-steroidal anti-inflammatory
drugs (NSAIDs) such as naproxen or ibuprofen do not affect
activity evoked due to hypoxia in vitro (65), suggesting that
the effect observed in the present study may be specific
to CND.
In conclusion, we observe an increase in inflammation
and changes in neuronal morphology after hypoxia-seizures
in neonates. Targeting inflammation may protect against
neonatal brain damage, reducing seizures during hypoxia,
reducing neuronal damage afterwards and improving later-
life neurological comorbidities, including anxiety-like behavior,
hippocampal function and susceptibility to seizures. Here, we
show the therapeutic potential of targeting inflammation as
a novel treatment for the long-term outcomes after neonatal
brain damage.
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